-
Paris Women's Fashion Week: the key trends
-
Bhuvneshwar returns to India's T20 squad for New Zealand tour
-
i-payout Introduces a New Approach to Payments, Closing the Beneficiary Information Gap
-
Asos says probing 'unauthorised activity' after phone alerts
-
New Generation of Crypto Miners Released by ASICID
-
Stocks climb as oil prices retreat under $100 per barrel
-
New investor forecasts LIV Golf teams could be worth $100 mn each
-
Neutrinos: space particles that change our view of universe
-
Shakira, Pique return to court over children visit arrangements
-
'Destined' Djokovic wins China Open, extending unbeaten record
-
Nobel physics prize hails 'ghostly messengers' from space
-
Iceland is 'critical outpost' for security, says Rubio during visit
-
France's Mistral unveils latest model in sovereign AI push
-
Israeli settlers beat AFP photographer covering West Bank
-
Stocks climb as oil prices retreat
-
'Gen Z has risen up': Tens of thousands demand better education in France
-
Vstock Transfer Names Securities Industry Veteran Erica Goodstein General Counsel and Chief Compliance Officer
-
$10 Million and Counting: Hola Prime Hits Major Trader Payout Milestone
-
Four Indonesian seamen return home after Somali pirate ordeal
-
UEFA investigate Ireland-Israel tunnel bustup after spitting claim
-
Crisis-striken Haiti postpones elections
-
Djokovic wins China Open and keeps unbeaten record after de Minaur retires
-
Germany arrests ex-spy chief on suspicion of giving secrets to foreign powers
-
Amsterdam's Rijksmuseum hosts 'homecoming' show for Willem de Kooning
-
Djokovic wins China Open after de Minaur retires
-
World Bank forecasts modest growth for Latin America, highlights climate risks
-
IMF warns cost-of-living shocks cause 'lasting deterioration' in affordability
-
'Afraid for my future': Tens of thousands demand better education in France
-
Alcaraz wins Japan Open for first title since injury return
-
Pakistan PM urges Imran Khan supporters to end protest march
-
'We're working to keep football clean', Turkish minister says
-
Alex Bodi își continuă expansiunea: planuri pentru deschiderea unui showroom ALIX LASERS la București
-
FIFA chief Infantino hit by Norwegian double complaint
-
STARTRADER Adds 20 Stock and ETF CFDs to Its 24/7 Trading Range
-
Exiled Catalan separatist leader Puigdemont cleared to return to Spain
-
Bulgaria searches for missing crew after drones hit more Black Sea ships
-
Stock markets climb as oil prices retreat
-
Alcaraz wins Japan Open for first title since return from injury
-
'No future': Thousands mass in France for high school protests
-
India, Qatar, S.Africa among nations who want to host 2036 Olympics
-
Nobel physics prize honours work on 'ghostly messengers' from outer space
-
Muchova squeaks out win over Osaka to reach China Open quarter-finals
-
Bulgaria searches for missing crew after drones hit two more ships in Black Sea
-
Kenya reports first-ever Ebola death
-
Le Pen vows drastic cost savings to prevent French 'default'
-
Tennis world No.1 Sinner's season over due to knee injury
-
'Eats through a straw': French teens wounded in high school protests
-
Yemen's Houthis claim attack on Riyadh airport, deny losing territory
-
Thousands mass in France for high school protests
-
7-Eleven exits India amid mounting competition
Moderna says US refusing to review mRNA-based flu shot
Vaccine manufacturer Moderna said Tuesday the US Food and Drug Administration was refusing to review an application for its first mRNA-based flu shot.
The move comes as the current iteration of the FDA has called for a reconsideration of approval procedures for certain vaccines, including for influenza -- proposed federal policy changes under President Donald Trump that have triggered widespread alarm among public health and medical professionals.
Moderna, a US company, said the agency's top vaccine regulator, Vinay Prasad, wrote in a letter that Moderna's clinical trial was not "adequate and well-controlled," and had not tested its experimental shot against the best product on the market.
In the large trial Moderna had compared its new vaccine with Fluarix, an approved flu shot from the company GSK.
Moderna said the rejection was "inconsistent with previous written communications" with the FDA branch that regulates biological products, including vaccines, known by the acronym CBER.
The decision "did not identify any safety or efficacy concerns with our product" and "does not further our shared goal of enhancing America's leadership in developing innovative medicines," Moderna CEO Stephane Bancel said in the statement.
"It should not be controversial to conduct a comprehensive review of a flu vaccine submission that uses an FDA-approved vaccine as a comparator in a study that was discussed and agreed on with CBER prior to starting."
Moderna said it had received a Refusal-to-File letter, which would indicate the application did not meet the requirements for substantive review. The company said it had requested a meeting to discuss the decision.
The letter did not identify any safety or efficacy concerns regarding the mRNA vaccine, said Moderna, which added the shot was accepted for review in the European Union, Canada and Australia.
During his first term Trump called mRNA technology a "modern-day miracle."
It was used during the Covid-19 pandemic to swiftly develop an immunization against the fast-spreading illness, and was credited with saving millions of lives.
Vaccines against Covid-19 are considered safe and effective by global health authorities, and protect against the most severe forms of the infection.
But in his second term, Trump has appointed Robert F. Kennedy Jr as his health chief, and the long-time vocal vaccine skeptic has spent the past year reshaping federal health agencies in his image.
That has meant spreading false information and sowing doubt about the safety and efficacy of vaccines widely known to be safe, and upending the pediatric immunization schedule.
Notably, Kennedy cut off federal research grants that funded mRNA development.
I.Meyer--BTB